Melinta Therapeutics Inc., of New Haven, Conn., said it entered a partnership with CARB-X, under which the firm will be awarded up to $6.2 million to develop its pyrrolocytosine compounds. Under the terms, Melinta will receive an initial award of up to $2.3 million, with the possibility of $3.9 million in additional awards based on the achievement of certain project milestones.